Developer docs
API playgroundTry for free, no card

Search company profiles

leadXpro AG

Full company profile

uuid000c4fe

Namestring
leadXpro AG
Legal namestring
leadXpro AG
Websiteurl
leadxpro.ch
Company typeenum
Private
Founded yearint
2015
Descriptiontext

leadXpro AG is a privately held Swiss Contract Research Organization (CRO) founded in 2015 and headquartered at Park Innovaare in Villigen, immediately adjacent to the Paul Scherrer Institute (PSI). The company provides structure-based drug discovery services focused on membrane proteins — a target class that includes GPCRs, ion channels, and transporters and is widely recognized as technically difficult. Its integrated service platform spans protein expression and purification, biophysical characterization using Grating-Coupled Interferometry (GCI), high-resolution structure determination via CryoEM and X-ray crystallography at the SwissFEL free-electron laser and SLS 2.0 synchrotron, computational chemistry and virtual screening, and lead discovery. AI/ML-driven construct design and, more recently, a partnership with Nuclera add cell-free protein synthesis to the workflow.

The company's customers are large pharmaceutical and biotechnology companies pursuing membrane-protein drug discovery programs. Engagement is project-based and structured around defined scientific deliverables; pricing is negotiated per project and not publicly disclosed. GTM is enterprise-focused, driven by direct business development outreach, scientific publications, and participation in industry events, supported by a website and LinkedIn presence. To date, leadXpro states it has characterized more than 110 drug targets. The leadership team blends ex-Roche, ex-Actelion/Idorsia, and PSI/ETH Zurich senior scientists, including a co-founder who is a group leader at PSI and the former head of Discovery Technologies at Roche Basel.

Revenue mechanics are entirely fee-for-service professional services, with no disclosed recurring or product revenue. The company has a single undated, undisclosed 2017 funding event in the input data and no evidence of further institutional capital raises; ownership appears founder-and-board controlled. Operational footprint is single-site (Villigen, Switzerland) but the company's global reach is exercised through the international client base that characterizes specialist CROs of this type.

Short descriptiontext

leadXpro AG is a Swiss CRO founded in 2015 that delivers structure-based drug discovery services for membrane protein targets, serving pharmaceutical and biotechnology companies through protein science, biophysics (GCI), CryoEM, SwissFEL/SLS 2.0 structural biology, and AI/ML-driven construct design.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersVilligen, Switzerland
HQ citystring
Villigen
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
structure-based drug discovery, membrane protein research, contract research organization, cryo-electron microscopy services, biophysical characterization
Industry1 code
PRIMARYHLAIALAB
Lead Optimization & Preclinical Candidate Selection
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
Contract Research Organization (Drug Discovery Services)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Services
TypeProfessional Services
Description

leadXpro operates as a CRO providing fee-for-service research engagements to pharmaceutical and biotechnology companies. Services include protein sciences, biophysics, structural biology, computational chemistry, and lead discovery. Revenue is generated through project-based contracts with pharmaceutical clients, typically structured around specific deliverable milestones.

leadxpro.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

leadXpro AG is a Swiss Contract Research Organization (CRO) that provides structure-based drug discovery services focused on membrane protein targets. The company delivers an integrated service platform spanning protein sciences (expression and purification), biophysics (Grating-Coupled Interferometry), structural biology (CryoEM, X-ray crystallography at SwissFEL and SLS 2.0), computational chemistry (virtual screening), and lead discovery to pharmaceutical and biotechnology clients. Since 2015, leadXpro has established protein science, biophysics, and structures for more than 110 drug targets.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 110+ drug targets structurally characterized
Product overview1 text field

leadXpro AG is a Swiss Contract Research Organization (CRO) founded in 2015 that provides an integrated service platform for structure-based drug discovery focused on membrane proteins. The company offers a comprehensive suite of services organized around a unified technology platform: Protein Sciences (expression and purification), Biophysics (using Grating-Coupled Interferometry), Structural Biology (CryoEM, SwissFEL, SLS 2.0), Computational Chemistry (virtual screening), and Lead Discovery. These services are supported by proprietary AI/ML-driven construct design capabilities. To date, leadXpro has established protein science, biophysics, and structures for more than 110 drug targets. The technology platform capabilities work together as an integrated workflow from target preparation through structural determination to lead identification.

Product and service5 records
1Protein Sciences Services
CategoryContract Research Services
Description

Protein science services for membrane protein target preparation, including expression, purification, and characterization to enable downstream drug discovery workflows for pharmaceutical and biotechnology clients.

2Biophysics Services
CategoryContract Research Services
Description

Biophysical characterization services using Grating-Coupled Interferometry (GCI) to measure binding kinetics and affinity of potential drug candidates with membrane protein targets.

3Structural Biology Services
CategoryContract Research Services
Description

Structural biology services employing CryoEM and X-ray crystallography (including SwissFEL and SLS 2.0 facilities at PSI) to determine atomic-resolution structures of membrane proteins for structure-based drug design.

4Computational Chemistry Services
CategoryContract Research Services
Description

Computational chemistry services including virtual screening and in silico modeling to support lead identification and optimization for membrane protein drug targets.

5Lead Discovery Services
CategoryContract Research Services
Description

Lead discovery services to identify and characterize small molecule leads that interact with membrane protein targets using integrated structural and computational approaches.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-19
Description

leadXpro is a PSI spin-off company with founders Gebhard Schertler (group leader at PSI) and Rafael Abela (scientific advisor at PSI). The company maintains close collaboration with PSI, leveraging SwissFEL X-ray free-electron laser and SLS 2.0 facilities for membrane protein structural biology research. John Millard serves as head of Technology Transfer Management at PSI.

2CSIC Barcelona
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-03-19
Description

Collaboration with researchers from CSIC (Spanish National Research Council) in Barcelona on photopharmacology research, specifically studying light-switchable drugs and their mechanism of action on beta-adrenergic receptors.

news.europawire.eu
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-19
Description

Scientific partnership to accelerate structure-based drug design for complex membrane proteins. The collaboration integrates Nuclera's eProtein Discovery cell-free protein synthesis technology with leadXpro's AI/ML-driven construct design and structural characterization expertise. Creates an AI-guided, iterative, end-to-end workflow linking in silico design with rapid experimental multiplex screening. Partnership will inform future integration of AI/ML capabilities into Nuclera's product portfolio and strengthen leadXpro's platform for producing and characterizing difficult membrane protein targets.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Proteros is a Munich-based structural biology CRO providing protein expression, crystallography, CryoEM and fragment-based lead discovery to pharma — a near-direct comparable to leadXpro across both membrane-protein and broader structural biology services for drug discovery.

TypeDirect peer
Description

Swedish structural biology CRO offering protein production, X-ray crystallography, CryoEM and biophysical services to pharmaceutical clients — directly comparable service catalog to leadXpro with similar project-fee business model and pharma clientele.

TypeDirect peer
Description

Specialist CRO focused on membrane protein expression, stabilization and structural biology — overlaps tightly with leadXpro's core niche of GPCRs, ion channels and transporters, serving similar pharma drug discovery teams.

TypeDirect peer
Description

UK-based integrated drug discovery CRO providing structural biology, biophysics, medicinal chemistry and protein production services to pharma — comparable integrated offering and similar size/scale profile to leadXpro.

TypeDirect peer
Description

Offers structural biology and drug discovery CRO services including protein production, CryoEM and membrane protein research, with a similar fee-for-service model serving pharma and biotech clients.

TypeBroad incumbent
Description

Large global CRO with structural biology, biophysics and protein sciences capabilities across a far broader service portfolio — competes for the same pharma R&D budgets as leadXpro but operates at much greater scale and with internal CryoEM/X-ray capacity.

TypeBroad incumbent
Description

Large drug-discovery CRO with integrated structural biology, biophysics and AI-driven discovery platforms — competes for the same outsourced pharma R&D workstreams as leadXpro but across many target classes and at greater scale.

TypeBroad incumbent
Description

Discovery arm of Eurofins offering structural biology, biophysics and drug discovery services to pharma — operates within a much larger testing and life-sciences portfolio with broader capability breadth than leadXpro.

TypeBroad incumbent
Description

Global CRO/CDMO with a sizable structural biology and drug discovery practice serving large pharma — competes for outsourced pharma R&D budgets but at massively greater scale and across all therapeutic areas.

10Syngene International
TypeRegional player
Description

Indian CRO providing integrated drug discovery and structural biology services to global pharma — comparable discovery-services offering and target clientele, but primarily serves from India-based operations rather than competing in Europe.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

leadXpro AG

Contract Research Organization (Drug Discovery Services)leadxpro.ch

leadXpro AG is a Swiss CRO founded in 2015 that delivers structure-based drug discovery services for membrane protein targets, serving pharmaceutical and biotechnology companies through protein science, biophysics (GCI), CryoEM, SwissFEL/SLS 2.0 structural biology, and AI/ML-driven construct design.

What leadXpro AG does

leadXpro AG is a privately held Swiss Contract Research Organization (CRO) founded in 2015 and headquartered at Park Innovaare in Villigen, immediately adjacent to the Paul Scherrer Institute (PSI). The company provides structure-based drug discovery services focused on membrane proteins — a target class that includes GPCRs, ion channels, and transporters and is widely recognized as technically difficult. Its integrated service platform spans protein expression and purification, biophysical characterization using Grating-Coupled Interferometry (GCI), high-resolution structure determination via CryoEM and X-ray crystallography at the SwissFEL free-electron laser and SLS 2.0 synchrotron, computational chemistry and virtual screening, and lead discovery. AI/ML-driven construct design and, more recently, a partnership with Nuclera add cell-free protein synthesis to the workflow.

The company's customers are large pharmaceutical and biotechnology companies pursuing membrane-protein drug discovery programs. Engagement is project-based and structured around defined scientific deliverables; pricing is negotiated per project and not publicly disclosed. GTM is enterprise-focused, driven by direct business development outreach, scientific publications, and participation in industry events, supported by a website and LinkedIn presence. To date, leadXpro states it has characterized more than 110 drug targets. The leadership team blends ex-Roche, ex-Actelion/Idorsia, and PSI/ETH Zurich senior scientists, including a co-founder who is a group leader at PSI and the former head of Discovery Technologies at Roche Basel.

Revenue mechanics are entirely fee-for-service professional services, with no disclosed recurring or product revenue. The company has a single undated, undisclosed 2017 funding event in the input data and no evidence of further institutional capital raises; ownership appears founder-and-board controlled. Operational footprint is single-site (Villigen, Switzerland) but the company's global reach is exercised through the international client base that characterizes specialist CROs of this type.

leadXpro AG firmographics

Firmographics
Name
leadXpro AG
Legal name
leadXpro AG
Website
https://leadxpro.ch
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
leadXpro AG is a Swiss CRO founded in 2015 that delivers structure-based drug discovery services for membrane protein targets, serving pharmaceutical and biotechnology companies through protein science, biophysics (GCI), CryoEM, SwissFEL/SLS 2.0 structural biology, and AI/ML-driven construct design.
Ownership category
akta.pro rank

leadXpro AG industry classification

Industry
Product category
Contract Research Organization (Drug Discovery Services)
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAIALAB
Lead Optimization & Preclinical Candidate Selection
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Structure-based drug discovery
  • Membrane protein research
  • Contract research organization
  • Cryo-electron microscopy services
  • Biophysical characterization

Where leadXpro AG is headquartered

Location

Headquarters

HQ city
Villigen
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

leadXpro AG business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Others

Revenue model

  1. Contract Research Services: leadXpro operates as a CRO providing fee-for-service research engagements to pharmaceutical and biotechnology companies. Services include protein sciences, biophysics, structural biology, computational chemistry, and lead discovery. Revenue is generated through project-based contracts with pharmaceutical clients, typically structured around specific deliverable milestones.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

leadXpro AG product offering

Product offering

Core offering

leadXpro AG is a Swiss Contract Research Organization (CRO) that provides structure-based drug discovery services focused on membrane protein targets. The company delivers an integrated service platform spanning protein sciences (expression and purification), biophysics (Grating-Coupled Interferometry), structural biology (CryoEM, X-ray crystallography at SwissFEL and SLS 2.0), computational chemistry (virtual screening), and lead discovery to pharmaceutical and biotechnology clients. Since 2015, leadXpro has established protein science, biophysics, and structures for more than 110 drug targets.

Product overview

leadXpro AG is a Swiss Contract Research Organization (CRO) founded in 2015 that provides an integrated service platform for structure-based drug discovery focused on membrane proteins. The company offers a comprehensive suite of services organized around a unified technology platform: Protein Sciences (expression and purification), Biophysics (using Grating-Coupled Interferometry), Structural Biology (CryoEM, SwissFEL, SLS 2.0), Computational Chemistry (virtual screening), and Lead Discovery. These services are supported by proprietary AI/ML-driven construct design capabilities. To date, leadXpro has established protein science, biophysics, and structures for more than 110 drug targets. The technology platform capabilities work together as an integrated workflow from target preparation through structural determination to lead identification.

Differentiator

Problem solved

Functional benefit

Products and services

  • Protein Sciences Services Protein science services for membrane protein target preparation, including expression, purification, and characterization to enable downstream drug discovery workflows for pharmaceutical and biotechnology clients.
  • Biophysics Services Biophysical characterization services using Grating-Coupled Interferometry (GCI) to measure binding kinetics and affinity of potential drug candidates with membrane protein targets.
  • Structural Biology Services Structural biology services employing CryoEM and X-ray crystallography (including SwissFEL and SLS 2.0 facilities at PSI) to determine atomic-resolution structures of membrane proteins for structure-based drug design.
  • Computational Chemistry Services Computational chemistry services including virtual screening and in silico modeling to support lead identification and optimization for membrane protein drug targets.
  • Lead Discovery Services Lead discovery services to identify and characterize small molecule leads that interact with membrane protein targets using integrated structural and computational approaches.

Quantifiable outcome

  • 110+ drug targets structurally characterized

Companies that use leadXpro AG

Customer profile

Segments2 records

Ideal customer profiles1 record

leadXpro AG technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature6 records

leadXpro AG partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Paul Scherrer Institute (PSI)coreStrategic or Co-development Partner · 19 March 2026leadXpro is a PSI spin-off company with founders Gebhard Schertler (group leader at PSI) and Rafael Abela (scientific advisor at PSI). The company maintains close collaboration with PSI, leveraging SwissFEL X-ray free-electron laser and SLS 2.0 facilities for membrane protein structural biology research. John Millard serves as head of Technology Transfer Management at PSI.
  • CSIC BarcelonaminorStrategic or Co-development Partner · 19 March 2026Collaboration with researchers from CSIC (Spanish National Research Council) in Barcelona on photopharmacology research, specifically studying light-switchable drugs and their mechanism of action on beta-adrenergic receptors.
  • NucleracoreStrategic or Co-development Partner · 19 February 2026Scientific partnership to accelerate structure-based drug design for complex membrane proteins. The collaboration integrates Nuclera's eProtein Discovery cell-free protein synthesis technology with leadXpro's AI/ML-driven construct design and structural characterization expertise. Creates an AI-guided, iterative, end-to-end workflow linking in silico design with rapid experimental multiplex screening. Partnership will inform future integration of AI/ML capabilities into Nuclera's product portfolio and strengthen leadXpro's platform for producing and characterizing difficult membrane protein targets.

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

leadXpro AG competitors and assessment

Company assessment

Direct peers

  • Proteros: Proteros is a Munich-based structural biology CRO providing protein expression, crystallography, CryoEM and fragment-based lead discovery to pharma — a near-direct comparable to leadXpro across both membrane-protein and broader structural biology services for drug discovery.
  • SARomics Biostructures: Swedish structural biology CRO offering protein production, X-ray crystallography, CryoEM and biophysical services to pharmaceutical clients — directly comparable service catalog to leadXpro with similar project-fee business model and pharma clientele.
  • Crelux: Specialist CRO focused on membrane protein expression, stabilization and structural biology — overlaps tightly with leadXpro's core niche of GPCRs, ion channels and transporters, serving similar pharma drug discovery teams.
  • Domainex: UK-based integrated drug discovery CRO providing structural biology, biophysics, medicinal chemistry and protein production services to pharma — comparable integrated offering and similar size/scale profile to leadXpro.
  • Creative Biolabs: Offers structural biology and drug discovery CRO services including protein production, CryoEM and membrane protein research, with a similar fee-for-service model serving pharma and biotech clients.

Broad incumbents

  • Charles River Laboratories: Large global CRO with structural biology, biophysics and protein sciences capabilities across a far broader service portfolio — competes for the same pharma R&D budgets as leadXpro but operates at much greater scale and with internal CryoEM/X-ray capacity.
  • Evotec: Large drug-discovery CRO with integrated structural biology, biophysics and AI-driven discovery platforms — competes for the same outsourced pharma R&D workstreams as leadXpro but across many target classes and at greater scale.
  • Eurofins Discovery Services: Discovery arm of Eurofins offering structural biology, biophysics and drug discovery services to pharma — operates within a much larger testing and life-sciences portfolio with broader capability breadth than leadXpro.
  • WuXi AppTec: Global CRO/CDMO with a sizable structural biology and drug discovery practice serving large pharma — competes for outsourced pharma R&D budgets but at massively greater scale and across all therapeutic areas.

Regional players

  • Syngene International: Indian CRO providing integrated drug discovery and structural biology services to global pharma — comparable discovery-services offering and target clientele, but primarily serves from India-based operations rather than competing in Europe.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

leadXpro AG social profiles

Digital presence

leadXpro AG financial estimates

Financial estimate

Revenue estimate

Valuation estimate

leadXpro AG leadership team

Management profile

Number of profiles

Profiles7 records

leadXpro AG funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

leadXpro AG M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about leadXpro AG

What does leadXpro AG do?

leadXpro AG is a Swiss Contract Research Organization (CRO) that provides structure-based drug discovery services focused on membrane protein targets. The company delivers an integrated service platform spanning protein sciences (expression and purification), biophysics (Grating-Coupled Interferometry), structural biology (CryoEM, X-ray crystallography at SwissFEL and SLS 2.0), computational chemistry (virtual screening), and lead discovery to pharmaceutical and biotechnology clients. Since 2015, leadXpro has established protein science, biophysics, and structures for more than 110 drug targets.

Is leadXpro AG a public or private company?

leadXpro AG is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was leadXpro AG founded?

leadXpro AG was founded in 2015. It employs 11 to 50 people.

Where is leadXpro AG based?

leadXpro AG is headquartered in Villigen, Switzerland, in the Europe region.

How does leadXpro AG make money?

One revenue line is on record: contract Research Services.

Who are leadXpro AG's main competitors?

Direct peers on record are Proteros, SARomics Biostructures, Crelux, Domainex and Creative Biolabs. Broad incumbents are Charles River Laboratories, Evotec, Eurofins Discovery Services and WuXi AppTec. Syngene International is listed as a regional player.

Does leadXpro AG have an API?

No public API is recorded for leadXpro AG.

What industry is leadXpro AG in?

leadXpro AG's product category is Contract Research Organization (Drug Discovery Services). Its primary akta.pro industry code is HLAIALAB, Lead Optimization & Preclinical Candidate Selection. Its NAICS code is 5417 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PharmiWeb.comCumulus Oncology and leadXpro Achieve Critical Milestone in GPR68 Drug Discovery ProjectCumulus Oncology licensed small molecule compounds and IP from leadXpro for GPR68 drug discovery, achieved in under 12 months. The collaboration will move to accelerated drug optimisation, with leadXpro receiving a revenue share. Cumulus plans to file for regulatory approval through its spinout GIO Therapeutics.GlobeNewswireCumulus Oncology and leadXpro Achieve Critical Milestone in GPR68 Drug Discovery ProjectCumulus Oncology licensed small molecule compounds and IP from leadXpro for its GPR68 drug discovery project. The collaboration, completed in under 12 months, will move to accelerated drug optimization, with leadXpro receiving a revenue share. Cumulus plans to file for regulatory approval through its GIO Therapeutics spinout.YahooCumulus Oncology and leadXpro Achieve Critical Milestone in GPR68 Drug Discovery ProjectCumulus Oncology licensed small molecule compounds and IP from leadXpro for its GPR68 drug discovery project. The collaboration, completed in under 12 months, will move to accelerated drug optimization, with leadXpro receiving a revenue share. Cumulus plans to file for regulatory approval through its spinout GIO Therapeutics.GlobeNewswireCumulus Oncology and leadXpro Announce Collaboration to Develop Small Molecules against Novel Cancer-Focused GPCR TargetsCumulus Oncology and leadXpro announced a collaboration to develop small molecules targeting a novel cancer-focused GPCR. The partnership will use leadXpro's structural biology expertise and Cumulus's oncology development resources, with resulting IP licensed into a new Cumulus company. leadXpro will retain an economic interest in the lead compound series.GlobeNewswireCumulus Oncology and leadXpro Announce Collaboration to Develop Small Molecules against Novel Cancer-Focused GPCR TargetsCumulus Oncology and leadXpro announced a collaboration to develop small molecules targeting a novel cancer-focused GPCR. The partnership will use leadXpro's structural biology expertise and Cumulus's oncology development resources, with resulting IP licensed into a new Cumulus company. leadXpro will retain an economic interest in the lead compound series.startupticker.chLeadXpro to collaborate with a British drug discovery companyleadXpro, an Aargau-based company, entered a strategic agreement with UK drug discovery firm Astex to use single-particle cryo-EM for membrane protein targets. The collaboration aims to generate high-resolution structures to aid small-molecule drug design, with both companies expecting cryo-EM to complement their existing X-ray crystallography efforts.startupticker.chLeadxpro collaborates with Sanofi on a research projectLeadxpro and Sanofi signed a collaboration agreement to combine structure-based drug discovery for a challenging drug target. Leadxpro will contribute protein sample generation and enable high-resolution cryo-EM structure determination to inform ligand interactions. The project aims to facilitate discovery and optimization of novel lead molecules.NewswireleadXpro and University of Zurich Announce Collaboration on Generation of Membrane Protein Target Directed SybodiesleadXpro and the University of Zurich announced a collaboration to generate sybodies targeting membrane proteins, with leadXpro providing purified samples and UZH applying its sybody platform. The project, supported by Innosuisse grant 25864.1 PFLS-LS, produced sybodies with up to pM affinities. leadXpro may acquire commercial applications, marking its first entry into biologics discovery.NewswireBASF and leadXpro Announce Research CollaborationBASF and leadXpro announced a research collaboration to use single particle cryo-electron microscopy for structure-based discovery of new active ingredients targeting membrane proteins. The partnership aims to expedite BASF's compound design programs, with financial details undisclosed.startupticker.chLeadXpro AG relies on Creoptix’s technologyLeadXpro AG, a lead discovery start-up, selected Creoptix's WAVE technology for its membrane protein drug discovery work. The company will use the WAVEdelta system to analyze kinetics and affinity in real-time, combining it with its expertise in assay development and structure-based methods.